While this drug’s development, clinical activity, and approval is remarkable, G12C is not a common mutation in pancreatic and colorectal cancers with KRAS mutations and sotorasib does not benefit patients with amplified or overexpressed KRAS. This evidence concerns the gene KRAS and colorectal cancer.